Physician profile
Michael Bastien
NPI 1053371096
$9,854.19
in general payments reported to CMS, 2019-2025
35 companies · $2,108 in 2025
The $2,108 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $240 · 2021: $2,009 · 2022: $1,625 · 2023: $1,376 · 2024: $1,292 · 2025: $2,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,776.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Icad, INC | $1,645.87 | 2021 | |
| Genzyme Corporation | $1,143.20 | 2021-2025 | |
| Abbvie INC. | $613.20 | 2021-2025 | Skyrizi |
| Incyte Corporation | $600.13 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $572.20 | 2019-2025 | Nemluvio |
| Amgen INC. | $539.09 | 2022-2025 | Otezla, Otezla |
| Journey Medical Corporation | $519.45 | 2022-2025 | Emrosi |
| Sun Pharmaceutical Industries INC. | $441.79 | 2019-2025 | Winlevi, Ilumya, Odomzo |
| Arcutis Biotherapeutics, INC. | $426.82 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $419.52 | 2020-2025 | Anzupgo, Adbry |
| Regeneron Healthcare Solutions, INC. | $371.51 | 2019-2025 | Libtayo, Dupixent |
| Epi Health, LLC | $341.75 | 2019-2022 | |
| Prugen, INC. Pharmaceuticals | $289.69 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $279.21 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Pfizer INC. | $239.32 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $196.34 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $179.70 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $174.20 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $142.45 | 2023 | Sotyktu |
| Ucb, INC. | $137.05 | 2022-2025 | Bimzelx |
| Allergan, INC. | $133.38 | 2019-2022 | |
| Biofrontera INC. | $88.17 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $54.67 | 2021 | |
| Botanix Sb INC | $47.86 | 2025 | Sofdra |
| Medimetriks Pharmaceuticals, INC. | $37.29 | 2023-2025 | Genadur |
| Blueprint Medicines Corporation | $27.84 | 2023 | |
| Sanofi-Aventis U.S. LLC | $24.55 | 2020 | |
| Medtronic, INC. | $24.31 | 2025 | Venaseal |
| Verrica Pharmaceuticals INC. | $24.25 | 2024 | Ycanth |
| Smith+Nephew, INC. | $23.30 | 2024 | Grafix Pl |
| Merz North America, INC. | $22.70 | 2022 | |
| Kyowa Kirin, INC. | $22.31 | 2023 | Poteligeo |
| Celgene Corporation | $19.16 | 2019 | |
| Dusa Pharmaceuticals, INC. | $18.16 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.75 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bastien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.